Abstract

We will study the differences in cellular protein expression between normal and tumoral kidney tissues as well as the profile of protein expression in different tumor types of renal neplasms, using proteomics technology. The continuation of this line of work will hopefully lead to the discovery of new molecular markers important in the diagnosis and treatment of renal cancer. We will develop techniques that assist in the identification of proteins in paraffin-fixed tissues. Comparison analyses will be performed using frozen tissues.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIASC009392-17
Application #
8158283
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
17
Fiscal Year
2010
Total Cost
$220,179
Indirect Cost

  Institution

Name
National Cancer Institute Division of Clinical Sciences
Department
Type
DUNS #
City
State
Country
Zip Code

  Publications

Finley, David S; Narula, Navneet; Valera, Vladimir A et al. (2011) Immunohistochemical basis for adjuvant anti-angiogenic targeted therapy for renal carcinoid: initial case report. Urol Oncol 29:85-9
Moore, Lee E; Boffetta, Paolo; Karami, Sara et al. (2010) Occupational trichloroethylene exposure and renal carcinoma risk: evidence of genetic susceptibility by reductive metabolism gene variants. Cancer Res 70:6527-36
Xie, Han; Valera, Vladimir A; Merino, Maria J et al. (2009) LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther 8:626-35
Timmers, Henri J L M; Pacak, Karel; Huynh, Thanh T et al. (2008) Biochemically silent abdominal paragangliomas in patients with mutations in the succinate dehydrogenase subunit B gene. J Clin Endocrinol Metab 93:4826-32
Yang, Youfeng; Padilla-Nash, Hesed M; Vira, Manish A et al. (2008) The UOK 257 cell line: a novel model for studies of the human Birt-Hogg-Dube gene pathway. Cancer Genet Cytogenet 180:100-9